Cytosorbents Corp 4
4 · Cytosorbents Corp · Filed Oct 29, 2014
Insider Transaction Report
Form 4
Gunton James T.
Director
Transactions
- Conversion
Series B 10% Convertible Preferred Stock
2014-10-09−44,075.48→ 0 total(indirect: By Partnership)→ Common Stock (121,755,470 underlying) - Conversion
Common Stock
2014-10-09+44,075.48→ 121,755,472 total(indirect: By Partnership)
Footnotes (3)
- [F1]These securities are held directly by NJTC Investment Fund, LP, of which the Reporting Person is a partner. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or any other purpose.
- [F2]On October 9, 2014, upon the election of the stockholders representing over 93% of the then-issued and outstanding Series B 10% Convertible Preferred Stock, each share of Series B 10% Convertible Preferred Stock converted into that number of shares of Common Stock equal to the stated value of $100.00 at a conversion price of $0.036. The Series B 10% Convertible Preferred Stock had no expiration or exercisable date.
- [F3]Includes payment-in-kind dividends issued to the Reporting Person by virtue of his ownership of Series B 10% Convertible Preferred Stock prior to the conversion discussed in footnote 2 above.